First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery.
Menichincheri, M., Bargiotti, A., Berthelsen, J., Bertrand, J.A., Bossi, R., Ciavolella, A., Cirla, A., Cristiani, C., Croci, V., D'Alessio, R., Fasolini, M., Fiorentini, F., Forte, B., Isacchi, A., Martina, K., Molinari, A., Montagnoli, A., Orsini, P., Orzi, F., Pesenti, E., Pezzetta, D., Pillan, A., Poggesi, I., Roletto, F., Scolaro, A., Tato, M., Tibolla, M., Valsasina, B., Varasi, M., Volpi, D., Santocanale, C., Vanotti, E.(2009) J Med Chem 52: 293-307
- PubMed: 19115845 
- DOI: 10.1021/jm800977q
- Primary Citation of Related Structures:  
3DU8 - PubMed Abstract: 
Cdc7 kinase is a key regulator of the S-phase of the cell cycle, known to promote the activation of DNA replication origins in eukaryotic organisms. Cdc7 inhibition can cause tumor-cell death in a p53-independent manner, supporting the rationale for developing Cdc7 inhibitors for the treatment of cancer ...